吸入用布地奈德混悬液结合硫酸特布他林雾化液治疗慢阻肺急性加重期的临床有效性

郎金杰

摘要：目的 分析吸入用布地奈德混悬液+特布他林在慢阻肺急性加重期的疗效。方法 选取124例在2020年3月-11月接受我院治疗的慢阻肺急性加重期患者，将其按随机双盲法均分为两组，对照A组62例给予硫酸特布他林雾化液治疗，观察B组62例给予吸入用布地奈德混悬液+硫酸特布他林雾化液治疗，对比两组的临床指标和发生不良反应情况。结果 观察B组PaO2、PaCO2、FEV1等临床指标显著的优于对照A组，不良反应发生率显著的比对照A组低，治疗总有效率显著的高于对照A组，两组比较有统计学意义（P<0.05）。结论 给予加重期的急性慢阻肺患者吸入用布地奈德混悬液+硫酸特布他林雾化液治疗，能够改善临床指标，降低发生不良反应的几率，疗效显著，值得在临床中广泛的推广和应用。

关键词：吸入用布地奈德混悬液;硫酸特布他林雾化液;慢阻肺急性加重期;临床有效性

[Abstract]Objective To analyze the efficacy of budesonide suspension combined with terbutaline in acute exacerbation of COPD. Methods 124 patients with acute exacerbation of COPD who were treated in our hospital from March to November 2020 were selected and randomly divided into two groups. 62 cases in control group A were treated with terbutaline sulfate atomization liquid，and 62 cases in observation group B were treated with budesonide suspension + terbutaline sulfate atomization liquid. The clinical indexes and adverse reactions of the two groups were compared. Results PaO2，PaCO2，FEV1 and other clinical indicators in group B were significantly better than those in group A，the incidence of adverse reactions was significantly lower than that in group A，and the total effective rate was significantly higher than that in group A，with statistical significance（P < 0.05）. Conclusion inhalation of budesonide suspension + terbutaline sulfate aerosol can improve the clinical indicators and reduce the probability of adverse reactions in patients with exacerbation of acute COPD. The curative effect is significant，which is worthy of wide promotion and application in clinic.

[Key words]budesonide suspension for inhalation;Terbutaline sulfate aerosol solution;Acute exacerbation of COPD;Clinical effectiveness

慢阻肺是一種临床中常见的慢性病，临床主要表现是气流受限，症状为咳嗽、咳痰、呼吸困难等。一旦病发慢阻肺就会损害患者呼吸功能，如果没有得到及时有效的治疗，就会在一定程度上损害循环系统功能，相对来说致残率和致死率都很高【1】。如果慢阻肺患者病情处于稳定期，只需要指导和干预康复肺功能即可，而一旦该病发展到急性加重期，患者就需要采取吸氧、药物如扩张支气管制剂、吸入用布地奈德混悬液等方式进行治疗。本研究选取124例在2020年3月-11月接受我院治疗的慢阻肺急性加重期患者作为研究对象，分析吸入用布地奈德混悬液+特布他林治疗慢阻肺急性加重期的疗效，取得显著的效果，现将开展过程做如下报道。……